
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Merck & Co
Deal Size : $493.0 million
Deal Type : Licensing Agreement
Merck Links up with Cyprumed in $493M Oral Peptide Deal
Details : Under the licensing agreement, MSD will acquire global rights to Cyprumed's platform for developing oral formulations of its peptide therapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 15, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Merck & Co
Deal Size : $493.0 million
Deal Type : Licensing Agreement
